FDA Advisory Committee Votes Against Compounding Of Coated Modified Release Drugs
FDA’s Pharmacy Compounding Advisory Committee votes to place coated modified release drugs on the “difficult-to-compound” list, thus barring these drugs from being compounded in the foreseeable future. The committee agreed with FDA’s recommendations that the complex formulation and the difficulty in manufacturing them precludes them from being compounded at the current time.
You may also be interested in...
A decade after Merck yanked Vioxx and Pfizer withdrew Bextra from the market because of cardiovascular concerns associated with the anti-inflammatory drugs, an FDA panel of outside experts on 23 February said those drugs' active ingredients – rofecoxib and valdecoxib, respectively – should not be compounded by US pharmacists.
Action responds to methanol contamination in hand sanitizers manufactured in Mexico and marketed in the US under numerous brands that followed a loosening standards for the products to drive a swift increase in production and meet surging demand during the coronavirus pandemic.
New import alert category and border testing required after reduced standards put dangerous sanitizers into hands of US consumers.